We are live on ! Find out more
NHAS

Novo Holdings A/S Portfolio holdings

AUM $1.23B
1-Year Est. Return 81.32%
This Fund
S&P 500
This Quarter Est. Return
+37.02%
1 Year Est. Return
+81.32%
3 Year Est. Return
+192.63%
5 Year Est. Return
+125.03%
10 Year Est. Return
+943.65%
AUM
$1.04B
AUM Growth
+$72.5M
Cap. Flow
-$117M
Cap. Flow %
-11.25%
Top 10 Hldgs %
98.88%
Holding
20
New
1
Increased
2
Reduced
2
Closed
6

Top Buys

Rank Stock Value
1
IVTY
Invuity, Inc
IVTY
+$11M
2
PEN icon
Penumbra
PEN
+$5.94M
3
NBRV
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
+$75.6K

Top Sells

Rank Stock Value
1
NVRO
NEVRO CORP.
NVRO
+$29M
2
ADAP
Adaptimmune Therapeutics
ADAP
+$16.9M
3
OTIC
Otonomy, Inc.
OTIC
+$15.6M
4
FLXN
Flexion Therapeutics, Inc.
FLXN
+$15.4M
5
AKBA icon
Akebia Therapeutics
AKBA
+$14.6M

Sector Composition

Rank Sector Weight
1 Healthcare 59.61%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ISEE
1
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$386M 37.06%
4,910,487
– –
VTI icon
2
Vanguard Total Stock Market ETF
VTI
$655B
$311M 29.87%
2,979,100
– –
INGN icon
3
Inogen
INGN
$171M
$142M 13.68%
3,549,320
– –
VGK icon
4
Vanguard FTSE Europe ETF
VGK
$30.1B
$105M 10.07%
2,101,000
– –
CLCD
5
DELISTED
CoLucid Pharmaceuticals, Inc.
CLCD
$25.6M 2.46%
3,056,563
– –
TBRA
6
DELISTED
Tobira Therapeutics, Inc. Common Stock
TBRA
$24.8M 2.39%
2,471,405
-225,000
-8% -$2.34M
PEN icon
7
Penumbra
PEN
$12.6B
$12.7M 1.22%
236,144
+131,200
+125% +$5.94M
NBRV
8
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$8.42M 0.81%
3,500
+31
+0.9% +$75.6K
IVTY
9
DELISTED
Invuity, Inc
IVTY
$8.16M 0.78%
+925,000
New +$11M
HTGM
10
DELISTED
HTG Molecular Diagnostics, Inc. Common Stock
HTGM
$5.58M 0.54%
7,112
– –
ELDN icon
11
Eledon Pharmaceuticals
ELDN
$276M
$4.11M 0.39%
2,907
-4,737
-62% -$8.25M
GKOS icon
12
Glaukos
GKOS
$8.92B
$1.85M 0.18%
75,000
– –
XENE icon
13
Xenon Pharmaceuticals
XENE
$6.36B
$1.03M 0.1%
127,563
– –
ADAP
14
DELISTED
Adaptimmune Therapeutics
ADAP
– –
-1,411,567
Closed -$16.9M
AKBA icon
15
Akebia Therapeutics
AKBA
$343M
– –
-1,516,387
Closed -$14.6M
NVRO
16
DELISTED
NEVRO CORP.
NVRO
– –
-625,704
Closed -$29M
OTIC
17
DELISTED
Otonomy, Inc.
OTIC
– –
-875,025
Closed -$15.6M
FLXN
18
DELISTED
Flexion Therapeutics, Inc.
FLXN
– –
-1,033,131
Closed -$15.4M

Similar funds

HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
CA
Cullinan Associates Louisville, Kentucky $1.24B AUM 28.12% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
WTA
Washington Trust Advisors Wellesley, Massachusetts $1.24B AUM 22.58% 1-Year Est. Return
CCA
Clearwater Capital Advisors Hoffman Estates, Illinois $1.24B AUM 15.23% 1-Year Est. Return

Novo Holdings A/S's Q4 2015 Portfolio in Review

As of Q4 2015, Novo Holdings A/S held 20 positions worth $1.04B, up 7.5% from $968M the previous quarter. Its ten largest holdings account for 99% of the portfolio.

Novo Holdings A/S withdrew a net $117M in Q4 2015, closing 6 positions and reducing 2 holdings. Its most notable exit was NEVRO CORP., an estimated $29M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 60% of assets, up from 56% a quarter earlier.

Against the trend, Novo Holdings A/S opened a new position in Invuity, Inc worth $8.16M.

  • Novo Holdings A/S's largest Q4 2015 buy was Invuity, Inc: 925,000 shares worth $8.16M.
  • Novo Holdings A/S added most to Penumbra in Q4 2015, an estimated $5.94M increase.
  • Novo Holdings A/S's biggest Q4 2015 reduction was Eledon Pharmaceuticals, cutting an estimated $8.25M.
  • Novo Holdings A/S fully exited NEVRO CORP. in Q4 2015, selling an estimated $29M.
  • Novo Holdings A/S's ten largest holdings make up 99% of its $1.04B portfolio in Q4 2015.
  • Novo Holdings A/S opened 1 new position and closed 6 in Q4 2015.
  • Novo Holdings A/S's portfolio value rose 7.5% quarter-over-quarter to $1.04B.

Based on Novo Holdings A/S's 13F filing for Q4 2015, filed 16 Feb 2016.